Chronic Heart Failure
New data question benefit of fluid restriction in chronic heart failure
CHICAGO — A new study that looked at how liberal vs. restrictive fluid restriction impacts health status for patients with chronic heart failure found no added risks or benefits with either strategy, researchers reported.
FDA approves expanded indication of furosemide injection for NYHA class IV heart failure
scPharmaceuticals Inc. announced the FDA approved the supplemental new drug application to expand the indication of its self-administered subcutaneous furosemide injection for patients with heart failure.
Extent of RV remodeling prior to CRT may predict survival in patients with chronic HF
More advanced right ventricular remodeling prior to cardiac resynchronization therapy for chronic HF was independently associated with reduced 5-year survival, researchers reported.
Chronic HF poses additional mortality threat for patients with COVID-19
Hospitalized patients with COVID-19 who have a history of chronic HF are at an increased risk for all-cause mortality, according to a study published in ESC Heart Failure.
Long-term glimepiride use may improve survival in patients with diabetes, chronic HF
Long-term use of glimepiride may improve survival and reduce hospitalizations in hospitalized patients with concomitant type 2 diabetes and chronic HF, researchers reported.
Different definitions of iron deficiency appear to impact prognosis in chronic HF
Different definitions of iron deficiency provide discordant results for prevalence and prognosis of chronic HF, according to research published in the Journal of the American College of Cardiology.
Patient-reported outcome measures detect clinically meaningful changes in chronic HF
Compared with NYHA class, patient-reported outcome measures were more likely to detect clinically meaningful changes in patients with chronic HF, researchers reported.
CANDLE
Noninferiority of canagliflozin (Invokana, Janssen) vs. the sulfonylurea glimepiride in HF outcomes.
VICTORIA: Vericiguat meets primary efficacy endpoint for treatment of worsening chronic HF
Merck announced that a soluble guanylate cyclase stimulator for the treatment of patients with worsening chronic HF with reduced ejection fraction met its primary efficacy endpoint in the phase 3 VICTORIA trial.